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At this moment, when the Brazilian people feels optimistic about 
the country development and a promising future, unfortunately it 
is time to face the reality that dengue, a disease caused by dengue 
flaviviruses of serotypes 1 through 4: dengue virus 1, 2, 3 and 4 
(DENV-1, 2, 3 and 4), remains a national tragedy. Over the last 31 
years we have been striken by successive outbreaks of this arboviral 
disease, transmitted to man by the mosquito Aedes aegypti. The 
incidence of dengue has been on an upward trend, and in the last 
decade 700,000 cases have been reported per year. Most Brazilian 
states are infested by Aedes aegypti and endure dengue transmission. 
The average age of dengue hemorrhagic fever patients has decreased, 
turning it into a disease that affects a rising proportion of children. 
In recent years dengue outbreaks have included many atypical cases, 
including myocarditis, hepatitis, meningoencephalitis and acute 
kidney failure, and  fatality rates have also increased.
Two papers on dengue, one from North and another from South 
Brazil, are being published in this issue of the Journal of the Brazilian 
Society of Tropical Medicine. One paper reports on the dengue 
situation in 2011 in Manaus, a large city of North Brazil, capital 
of the State of Amazonas. Patients with acute febrile illness were 
tested for dengue by reverse transcription polymerase chain reaction 
(RT-PCR) and nested PCR, and 137 of 432 were found to be positive. 
Among these, 51 had DENV-2, 31 had DENV-4, 22 had DENV-3 and 
17 had DENV-1. Co-infections by more than one DENV serotype 
were also observed: DENV-4 and -3 in 6 cases, DENV-1 and -4 in 
5 cases, DENV-1 and -2 in 3 cases, and DENV-2 and -3 in 2 cases. 
This is the first report on the simultaneous circulation of the four 
dengue serotypes in the same place in Brazil, and provides clear 
evidence of dengue hyperendemicity, a situation that will probably 
lead to increasing morbidity, severe forms of disease, and mortality.
The second paper reports a study on molecular epidemiology 
of DENV isolates in the State of Parana, South Brazil, a subtropical 
region less infested by Aedes aegypti, where dengue outbreaks are less 
frequent. Ribonucleic acid (RNA) extracts of virus isolates from 11 
counties were tested by RT-PCR and nested PCR, and sequences 
in the genomic region of capsid/premembrane junction of DENV-
1 and 2 were analyzed. Four patients were co-infected with both 
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DENV-1 and 2. DENV-1 sequences in Parana were 95-100% similar 
to those of other DENV-1 Brazilian strains belonging to genotype 
V, the only genotype circulating in Brazil thus far. The replacements 
of methionine by alanine (amino acid 69) and isoleucine by valine 
(amino acid 117), observed in these sequences had been previously 
detected in DENV-1 strains isolated in Rio de Janeiro and São Paulo, 
the likely origin of this virus. Similarly, DENV-2 sequences were 
98-100% similar to those of other DENV-2 strains of genotype I 
(American/Asian). That genotype of DENV-2, which has been 
associated with dengue hemorrhagic fever, has predominated in 
Brazil during the 19 years of its circulation (1991 - 2008).
Thus, both papers presently published call attention to the 
hyperendemicity of DENV in Brazil, with increased genetic diversity 
and serious consequences, such as an expanded range of pathogenic 
properties, increased transmissibility and virulence. How did we 
reach this level of dengue endemicity? How to control dengue in 
Brazil? The most important tool for dengue prevention so far is 
vector control. However, we have not been successful in the fight 
against the mosquito vector. Despite efforts to control Aedes aegypti, a 
hyper-endemic situation has remained in Brazil, with large outbreaks 
involving all four dengue serotypes (DENV-1 to 4). Therefore, it is 
regrettable that an expectation of short term reduction in dengue 
incidence  has been raised by some public health authorities, and by 
the press, attributed to a triumph of fight against the vector. At this 
point, a dengue vaccine, which will probably become available in 
the next few years, remains as the great hope to control this disease 
in the Brazilian population.
Last but not least, other arboviruses such as yellow fever, Saint 
Louis encephalitis, oropouche and mayaro are also causing outbreaks 
and sporadic cases of febrile disease in Brazil. Infections by these 
agents are commonly confused with dengue and frequently remain 
misdiagnosed.
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